Mycovia Pharmaceuticals

Mycovia Pharmaceuticals is dedicated to developing breakthrough therapies in women's health and dermatology. Our lead product candidate, VT-1161, is for the treatment of recurrent vulvovaginal candidiasis (RVVC), a yeast infection that affects millions of women each year, often causing distressing physical discomfort and negative impacts on mental health.